Response to immunotherapy plus anti-angiogenic agent combination challenges hepatocellular carcinoma prognostic scores.

This new UHPI score identifies three groups with different prognosis, but with no clear therapeutic guidance. Moreover, this model's predictive ability is now challenged in the era of combination therapies where durable responses are more commonly observed, and where response criteria remain to be defined.